web analytics
-0.8 C
Munich
Saturday, November 26, 2022

This is the Time of Year for Cannabis Science Inc (OTCMKTS:CBIS)

Cannabis Science Inc (OTCMKTS:CBIS) is entering the time of year when it usually starts to get hot. The stock has been at the forefront of the pot stock revolution that has swept up small caps and produced most of the biggest winners in recent penny stock history. Now that the sector is heating up again and CBIS is at the bottom of its trading range Investors are taking another look.

CBIS is a stock with a long history of EPIC moves; just over the past 3 years CBIS has had no less than 3 spectacular moves from $0.01, $0.03, and $0.05 starts to highs over $0.25 twice and $0.30 the last time. CBIS has its detractors no doubt but none can argue that this is easily one of the most volatile and explosive pot stocks of them all.

Pot stocks are heating up again big time; according to a recent report from MMJ Business Daily, 2015 is expected not only to see more investment dollars flow into the market but it could even outpace the growth rate seen in 2014. States like Nevada, Illinois, Massachusetts, Oregon, and Alaska have all been identified as industry drivers this year. Furthermore, the rise in “big money” from some major investment funds has just started to hit the sector.

Cannabis Science Inc (OTCMKTS:CBIS) is one of the original MJ stocks to trade on the bb’s; the Company specializes in global cannabis formulation-based drug development and consulting. CBIS capitalizes on its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory.

About 2 years ago Cannabis Science made a number of acquisitions in the cannabis sector that currently drive future growth. CBIS 2 most important drugs in development are:

The CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”

The drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phyto cannabinoid-based therapeutics for drug resistant HIV infection.”

To Find out the inside Scoop on CBIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Since inception Cannabis Science operated business in a variety of industries under multiple aliases, “Patriot Holdings” in 1996, “National Healthcare Technology, Inc.” in 1999, “Special Stone Surfaces” in 2005, “Brighton Oil & Gas” in 2007, and “Gulf Onshore, Inc.” in 2008. These scattered and unsuccessful business ventures ranged from biotechnological R&D, oil and gas exploration, mineral leasing and significant M&A activities.

In recent news CBIS said they are in the final stages of its preparations to launch new products throughout the California market, including extracts, oils, tinctures, tablets, and creams.

The California launch was made possible by a renegotiation of the Cannabis Science agreement with Apothecary Genetics Investments LLC. The new agreement enabled Cannabis Science to purchase and license two northern California production farms with a combined total of 51 acres. The purchase included all related equipment for cannabis cultivation and production for the state’s substantial medical cannabis market and gives Apothecary Genetics the right to sell Cannabis Science formulations throughout the State of California.

Mr. Raymond C. Dabney, President & CEO, the man who has been behind CBIS from the beginning said “All that’s left now is to finish work on the packaging and the labeling, and that should only take a matter of days, The products and the formulation are there. We’re ready to launch in California and we’re excited, as I’m sure many self-medicating patients are.”

Looking at CBIS and all its vast and varied operating divisions, one might think they are a revenue generating power house but you would be very wrong; in fact CBIS has very limited operations, with minimal revenues to date and the Company continues to burn cash every quarter. This unfortunate situation has led to continued massive dilution with CBIS share count more than tripling over the past 3 years from 241,920,574 total shares out on 4 November, 2011 as compared to 934,923,906 total shares as of 17 November, 2014. Issuing shares is clearly nothing new to the shell either as the Company affected 3 reverse stock splits before it even became CBIS.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $57 million market valuation CBIS is one of the original pot stocks that investors love to flock to when the sector heats up evidenced by no less than 3 spectacular runs in recent years. As pot stocks heat up CBIS deserves to be at the top of Investors radars. CBIS is a stock to watch.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CBIS either long or short and we have not been compensated for this article.

Ali Raza
A journalist, with experience in web journalism and marketing. Ali holds a master degree in finance and enjoys writing about cryptocurrencies and fintech. Ali’s work has been published on a number of cryptocurrency publications.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.